Topiramate vs Metformin on Cardio-Metabolic Profile in Schizophrenia on Atypical Antipsychotics
Status:
Recruiting
Trial end date:
2023-07-30
Target enrollment:
Participant gender:
Summary
Metabolic syndrome is common in patients of schizophrenia. It can add to morbidity, loss of
functionality and discontinuation of antipsychotic medication. Apart from metformin, there
are limited treatment options as add on-s to antipsychotics for treatment of metabolic
syndrome. There have been placebo-controlled studies of Topiramate as an adjuvant but the
present study would be the first head-on trial between these drugs for treatment of metabolic
syndrome in patients of schizophrenia.
If the outcome measures show a significant improvement with add on topiramate when compared
with Metformin, then add on Topiramate can be a preferred treatment for metabolic syndrome in
patients with schizophrenia on atypical antipsychotics. The adverse effects of Metformin can
be side-stepped and Topiramate can also be given in conditions which are contraindications
for Metformin. Thus, Topiramate can be a good alternative to metformin especially in
conditions like liver, cardiac and renal impairment where metformin use should be avoided.
Topiramate can not only improve metabolic parameters but can also have a beneficial effect on
the symptom severity of schizophrenia. Thus, it can be a good augmentation drug to be used
along with antipsychotics in these patients.
Phase:
Phase 4
Details
Lead Sponsor:
All India Institute of Medical Sciences, Bhubaneswar